The latest information on the potential impact of viral mutations on the performance of the Mesa Biotech Inc. Accula SARS-CoV-2 Test

If your email program has trouble displaying this email, view as a webpage. Update: SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests  Today, the U.S. Food and Drug Administration (FDA) posted an update to the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information.  The update added new information about a potential impact on the performance of the Mesa Biotech Inc. Accula SARS-CoV-2 Test due to a genetic mutation at positions 28877-28878 (AG to TC) in patient samples.  Read More Questions? If you have questions about this update, email COVID19DX@fda.hhs.gov

Follow us on Twitter at @FDADeviceInfo Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA